Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz268.005
Abstract: Abstract Background BRAF genomic alterations (GA) occur in multiple tumor types and BRAF/MEK targeted therapies are approved in melanoma and NSCLC. Diverse mechanisms of AR to these therapies have been proposed but have not been… read more here.
Keywords: medicine; shareholder stockholder; stock options; stockholder stock ... See more keywords
Phosphatidylserine Suppresses T Cells Through GPR174, and Co-Inhibition of Adenosine Receptors and GPR174 Synergistically Enhances Th1 Cytokine Production
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz451.017
Abstract: Abstract Background Extracellular phosphatidylserine (PS) is a potent modulator of immune responses. In addition to exposure during apoptosis, PS is observed on activated platelets, leukocytes, endothelial cells, tumor cells, and exosomes. While PS exposed during… read more here.
Keywords: gpr174; omeros corporation; stock options; stockholder stock ... See more keywords